| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/03/2001 | WO2001030762A1 Imidazol-4-ylmethanols use as inhibitors of steroid c17-20 lyase |
| 05/03/2001 | WO2001030761A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 05/03/2001 | WO2001030759A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | WO2001030758A1 Drugs for the treatment of malignant tumours |
| 05/03/2001 | WO2001030734A1 Novel hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 05/03/2001 | WO2001030448A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030394A1 Treatment of cancer |
| 05/03/2001 | WO2001030393A2 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
| 05/03/2001 | WO2001030382A1 Method of inducing and/or enhancing an immune response to tumor antigens |
| 05/03/2001 | WO2001030381A2 Use of csf-1 inhibitors |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030366A2 Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases |
| 05/03/2001 | WO2001030362A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030351A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | WO2001030343A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | WO2001030341A1 Cyclooxygenase-2 expression inhibitors |
| 05/03/2001 | WO2001030333A2 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | WO2001030328A2 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | WO2001030319A1 New and improved formulation for paclitaxel |
| 05/03/2001 | WO2001005968A9 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 05/03/2001 | WO2001002423A3 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith |
| 05/03/2001 | WO2001001139A3 Incorporation and appliations of biomolecular interactions within a carrier |
| 05/03/2001 | WO2000078802A3 Secreted polypeptides and corresponding polynucleotides |
| 05/03/2001 | WO2000076537A3 Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases |
| 05/03/2001 | WO2000074712A3 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 05/03/2001 | WO2000072876A3 Prevention and treatment of amyloidogenic disease |
| 05/03/2001 | WO2000068263A3 Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| 05/03/2001 | WO2000065028A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 05/03/2001 | US20010000730 Method of enhancing the efficacy of anti-tumor agents |
| 05/03/2001 | DE19951702A1 Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten Use of 2-amino-3,4-dihydro-quinazolines for the preparation of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions |
| 05/03/2001 | DE19951671A1 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist and its use as an endothelin antagonist |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | DE19949179A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid |
| 05/03/2001 | DE10038203A1 Implantable active agent depot, useful e.g. in local tumor treatment or gene therapy, comprising drug-containing, cubic phase forming lipid matrix containing modifier molecule to control release kinetics |
| 05/03/2001 | CA2721011A1 Modified gp100 and uses thereof |
| 05/03/2001 | CA2389583A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | CA2389522A1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 05/03/2001 | CA2389171A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | CA2389169A1 Novel limonoids for use particularly in the treatment of cancer and method for producing the same |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2389020A1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | CA2389012A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | CA2388998A1 Treatment of cancer |
| 05/03/2001 | CA2388965A1 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | CA2388942A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | CA2388924A1 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | CA2388617A1 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | CA2388613A1 New and improved formulation for paclitaxel |
| 05/03/2001 | CA2388599A1 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | CA2388535A1 Ligand activated transcriptional regulator proteins |
| 05/03/2001 | CA2388508A1 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| 05/03/2001 | CA2388483A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | CA2388337A1 Method of inducing and/or enhancing an immune response to tumor antigens |
| 05/03/2001 | CA2388332A1 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 05/03/2001 | CA2388298A1 The use of csf-1 inhibitors |
| 05/03/2001 | CA2387921A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 05/03/2001 | CA2387901A1 Salt form of a conjugate useful in the treatment of prostate cancer |
| 05/03/2001 | CA2387869A1 Imidazol-4-ylmethanols use as inhibitors of steroid c17-20 lyase |
| 05/03/2001 | CA2387857A1 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | CA2387648A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | CA2387378A1 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | CA2386926A1 Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin |
| 05/03/2001 | CA2386750A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | CA2385929A1 Use of gdnf for treating corneal defects |
| 05/02/2001 | EP1096022A1 Immuno-stimulating polysaccharide substance from Phellinus spp. strain and use thereof |
| 05/02/2001 | EP1096009A1 G-protein coupled receptor-like Polypeptide |
| 05/02/2001 | EP1096008A2 Human G protein-coupled receptor, PFI-014 |
| 05/02/2001 | EP1095940A2 Derivatives of 9-(3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphto[2,3-d][1,3]dioxol-6(5aH)-one, method for their preparation and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095936A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
| 05/02/2001 | EP1095662A1 New vaccine composition and use of surfactants as immuno-adjuvant |
| 05/02/2001 | EP1095657A2 Compositions for the regulation of cytokine activity |
| 05/02/2001 | EP1095274A1 Trifunctional reagent for conjugation to a biomolecule |
| 05/02/2001 | EP1095183A2 Methods for the diagnosis and treatment of lung cancer |
| 05/02/2001 | EP1095142A2 Molecules associated with cell proliferation |
| 05/02/2001 | EP1095062A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 05/02/2001 | EP1095061A1 Peptides based on the sequence of human lactoferrin and their use |
| 05/02/2001 | EP1095060A1 Galectin 11 |
| 05/02/2001 | EP1095057A1 Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof |
| 05/02/2001 | EP1095039A2 New pharmaceutically active compounds |
| 05/02/2001 | EP1095038A1 Antagonists of gonadotropin releasing hormone |
| 05/02/2001 | EP1095031A1 Antiviral macrocyclic compounds |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095018A1 Aminoiminoquinone and aminoquinone alkaloid compounds as caspase inhibitors |
| 05/02/2001 | EP1095003A1 Cytokine production and tyrosine kinase inhibitors |
| 05/02/2001 | EP1094839A1 FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH $i(IN VIVO) RADIOSENSITIZING PROPERTIES |
| 05/02/2001 | EP1094816A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 05/02/2001 | EP1094813A2 Use of piperine for treating skin pigmentation disorders |
| 05/02/2001 | EP1094812A1 Angiogenesis inhibitors |
| 05/02/2001 | EP1094800A2 PEPTIDYL-PROLYL $i(CIS)-TRANS ISOMERASE INHIBITORS AND USES THEREFOR |
| 05/02/2001 | EP1094798A2 INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| 05/02/2001 | EP1071329A4 Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 05/02/2001 | EP0984959A4 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| 05/02/2001 | EP0983257A4 Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| 05/02/2001 | EP0973392A4 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/02/2001 | EP0966427B1 Preparation of acid amides and metallisation of compounds |
| 05/02/2001 | EP0863866B1 Butyrate prodrugs of lactic acid |
| 05/02/2001 | EP0817860B1 Pseudotyped retroviral particles |
| 05/02/2001 | EP0769947B1 Indolinone compounds for the treatment of disease |